<DOC>
	<DOC>NCT01850641</DOC>
	<brief_summary>The purpose of this study is to investigate the safety and efficacy when administering PA21 with calcium carbonate in hemodialysis patients with hyperphosphatemia for 12 weeks.</brief_summary>
	<brief_title>A Phase III Study of PA21 With Calcium Carbonate in Hemodialysis Patients With Hyperphosphatemia</brief_title>
	<detailed_description />
	<mesh_term>Hyperphosphatemia</mesh_term>
	<mesh_term>Calcium Carbonate</mesh_term>
	<criteria>Receiving stable maintenance hemodialysis 3 times a week Dialysis patients with hyperphosphatemia Patients having history of a pronounced brain / cardiovascular disorder Patients having severe gastrointestinal disorders Patients having severe hepatic disorders</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2014</verification_date>
	<keyword>Hemodialysis</keyword>
	<keyword>Hyperphosphatemia</keyword>
</DOC>